Study on Managing High-Risk HPV and Precancerous Cervical Lesions in Women Aged 18 to 46

What this Trial Is About

This research aims to develop clinical guidelines for managing women who test positive for high-risk human papillomavirus HPV HR and have cervical lesions. The study focuses on women aged 18 to 46 and evaluates how HPV HR testing can be integrated into screening programs for women aged 35, 45, and 55. The study also compares outcomes for women vaccinated against HPV with Gardasil-9 and those who are unvaccinated. Participants are grouped based on HPV vaccination status those not vaccinated against HPV and those who received the Gardasil-9 vaccine. The study observes spontaneous regression or progression of cervical lesions over a two-year period. This is assessed using HPV HR genotyping, viral load, methylation results, and CinTec plus testing. During the study, participants undergo regular cervical biopsies, colposcopy, and HPV testing to monitor lesion changes. Researchers evaluate outcomes such as lesion regression or progression over two years. The study tracks these results without providing active treatment and includes follow-up assessments to better understand the natural course of cervical lesions in both vaccinated and unvaccinated women.

Epidemiological Factors and Optimization of Conservative Approaches to Precancerous Lesions of Female Reproductive Organs